An American (pre-proof) paper by X. Lin et al titled “Transplacental Transmission of the COVID-19 Vaccine mRNA: Evidence from Placental, Maternal and Cord Blood Analyses Post-Vaccination” posted 1 February 2024 has found exactly that in two women after giving birth.
The main text is less than five pages so it is a quick read.
Patient 1 was 34 years old and had received 4 doses (3 Pfizer and 1 Moderna), the last dose was Moderna administered 2 days before cesarean section delivery. She also reportedly had COVID-19 one month before delivery.
Patient 2 was 33 years old and had received 2 doses (Pfizer), the last dose administered 10 days before vaginal delivery. No umbilical cord or maternal blood samples were taken for Patient 2. She had no history of COVID-19 infection.
The results:
In the placentas, 23% and 42% of the original integrity were retained in patients 1 and 2, respectively. The vaccine mRNA in the maternal blood showed a high integrity level of 85%; however, in the cord blood, it decreased to 13% of the original vaccine mRNA’s integrity.
The paper concludes:
Our findings suggest that the vaccine mRNA is not localized to the injection site and can spread systemically to the placenta and umbilical cord blood.
Told ya.
Even though the study merely involved two women, it at least confirms what was suspected even before the rollout of the so-called vaccines.
The paper conveniently states that both babies were healthy. It would be interesting if the researchers had tested to see if the babies had mRNA in their system or at least followed up on their general health.
But fret not, the researchers wrote the usual spiel about how there are “plausible risks” but also “plausible benefits” regarding the so-called vaccines.
The evidence overwhelmingly supports the COVID-19 vaccine’s effectiveness in mitigating the morbidity and mortality related to the COVID-19 disease in pregnant and non-pregnant individuals. The widespread acceptance and proven safety of mRNA vaccines during the COVID-19 pandemic have opened doors for other mRNA therapies. While gene therapy, particularly mRNA-based treatments, shows promise, research on its perinatal delivery is still emerging. … Although introducing mRNA to the fetus may pose potentially plausible risks, it may also have biologically plausible benefits.
What is admitted to be “gene therapy” is “still emerging” but it has “proven safety”. Right.
Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!
